Transcatheter pulmonary valve replacement is a viable alternative to surgical replacement, though challenges remain regarding delivery systems, landing zones, optimal timing, and affordability.
Does transcatheter pulmonary valve replacement (tPVR) improve outcomes in patients with right ventricular outflow tract (RVOT) dysfunction?
Transcatheter pulmonary valve replacement is a viable and effective alternative to surgical conduit replacement for patients with RVOT dysfunction, though careful patient selection and procedural planning are required to mitigate risks like stent fracture.
Transcatheter pulmonary valve replacement (tPVR) has evolved into a viable alternative to surgical conduit or bioprosthetic valve replacement. This procedure has paved the way for a more advanced approach to congenital and structural interventional cardiology. Although many successes have been noted, there are still a number of challenges with this procedure, including large delivery systems, the need for a conduit or a bioprosthetic valve as a landing zone for the valve, optimal timing of the procedure to prevent right ventricular failure, arrhythmias, and possible death. Research is ongoing to broaden the use of this technology when treating patients with dilated right ventricular outflow tracts, and early experience with a self-expanding valve model has been reported. Affordability is an important factor that must be considered especially in developing nations. The aim of this review is to emphasize the advancement of tPVR, the benefits and challenges of valve implantation, the current state, and the future innovations associated with this approach.
Ghawi et al. (Tue,) conducted a review in Congenital and structural heart disease. Transcatheter pulmonary valve replacement (tPVR) was evaluated. Transcatheter pulmonary valve replacement is a viable alternative to surgical replacement, though challenges remain regarding delivery systems, landing zones, optimal timing, and affordability.